STACEY DALE: Open Payments
NPI 1336848324 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,564 in 77 payments from 12 companies in 2025. Trend: 2023 $132 · 2024 $926 · 2025 $1,564
Food & beverage: $1,552Education: $12
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 21 | $442 |
| Vanda Pharmaceuticals Inc. | 11 | $231 |
| ABBVIE INC. | 15 | $207 |
| Otsuka America Pharmaceutical, Inc. | 9 | $179 |
| E.R. Squibb & Sons, L.L.C. | 3 | $154 |
| Lundbeck LLC | 4 | $84 |
| Axsome Therapeutics, Inc. | 4 | $75 |
| Supernus Pharmaceuticals, Inc. | 3 | $55 |
| Teva Pharmaceuticals USA, Inc. | 3 | $47 |
| Janssen Pharmaceuticals, Inc | 2 | $46 |
Products named: INGREZZA, VRAYLAR, REXULTI, COBENFY, HETLIOZ, FANAPT, Auvelity, ABILIFY ASIMTUFII.
Industry payments across MD — which companies pay providers there.
